Form D · Biotechnology
GENOCEA BIOSCIENCES, INC.
Cambridge, MA · CIK 0001457612
Offering snapshot reported Aug 3, 2020 · SEC filing
- Reported sold
- $75.5M Offering amount: $79.9M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 3, 2020 | Initial | $75,508,015 | No comparison | 18 | SEC filing |
| Feb 27, 2019 | Initial | $12,066,763 | No comparison | 9 | SEC filing |
| Oct 10, 2013 | Initial | $400,000 | No comparison | 1 | SEC filing |
| Jul 2, 2013 | Amendment | $30,500,000 | $15,250,000vs Oct 11, 2012 | 21 | SEC filing |
| Oct 11, 2012 | Initial | $15,250,000 | No comparison | 21 | SEC filing |
| Jan 3, 2011 | Initial | $35,099,999 | No comparison | 16 | SEC filing |
| Feb 25, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $4.79M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-372378
TOTAL REMAINING TO BE SOLD REPRESENTS PRE-FUNDED WARRANTS AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK; SUCH PRE-FUNDED WARRANT AND WARRANTS HAVE NOT YET BEEN EXERCISED.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| STIFEL, NICOLAUS & COMPANY, INCORPORATED | 793 |
Source: Form D, filed Aug 3, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Girish Aakalu | Executive |
| Michael Alfieri | Executive |
| Kenneth Bate | Director |
| Ali Behbahani | Director |
| Kevin Bitterman | Director |
| Katrine Bosley | Director |
| Pamela Carroll | Executive |
| Leon Chen | Director |
| William Clark | Executive |
| Ronald Cooper | Director |
| Thomas Davis | Executive |
| Diantha Duvall | Executive |
| Dalton Einhorn | Director, Executive |
| Robert E. Farrell Jr. | Executive |
| Jessica Flechtner | Executive |
| Simeon George | Director |
| Paul Giannasca | Executive |
| Seth Hetherington | Executive |
| Michael Higgins | Director |
| Steve Hoffman | Director |
| Stephen Hoffman | Director |
| Howard Mayer | Director |
| Derek Meisner | Executive |
| Robert Paull | Director |
| Gisela Schwab | Director |
| George Siber | Director |
| Narinder Singh | Executive |
| Ravi Venkataramani | Executive |
| Asish Xavier | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Acorn Park Drive
Cambridge, MA, 02140
Cambridge, MA, 02140